The use of COA in patient-centered drug development: part 1

Show notes

From introduction to interpretation, join Dan O’Connor and Chad Gwaltney as they explore how best to meet the expectations of regulatory authorities. Including: demystifying COA guidance documents and discussing how they became an integral part of the regulatory landscape.